Incyte Corporation (NASDAQ:INCY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 10, Incyte Corporation reported that the company’s Q4 2025 revenue climbed 28% to $1.51 billion, while full-year sales reached$5.14 billion. The company’s growth was largely propelled by its flagship product, Jakafi, which achieved annual sales of $3.093 billion, and the rapid expansion of Opzelura in the atopic dermatitis and vitiligo markets. The company’s core business, excluding Jakafi, ...